construction release_alert

Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.

cancel

A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination with Nivolumab or Nivolumab and Ipilimumab for Adults with Extensive-Stage Small Cell Lung Cancer

Clinical Trial Grant

Duke Scholars

Principal Investigator Neal Edward Ready Medicine, Medical Oncology

Administered By

Duke Cancer Institute

Awarded By

AbbVie Inc.

Start Date

September 5, 2017

End Date

September 1, 2020

Administered By

Duke Cancer Institute

Awarded By

AbbVie Inc.

Start Date

September 5, 2017

End Date

September 1, 2020